North Carolina is currently home to 2643 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
NCT05538208
Recruiting
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of prolifer... Read More
Gender:
ALL
Ages:
Between 8 years and 20 years
Trial Updated:
04/30/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Lupus Nephritis
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: AdventHealth Infusion Center Asheville, Asheville, North Carolina
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
NCT05261139
Recruiting
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for... Read More
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
04/30/2025
Locations: Clinical and Translational Research Center, Chapel Hill, North Carolina
Conditions: COVID-19
Register for Updates
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
NCT05096481
Recruiting
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/30/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Register for Updates
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
NCT04256317
Recruiting
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the fi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Duke University, Durham, North Carolina
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Register for Updates
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941
Recruiting
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Advanced Epithelioid Sarcoma, Advanced Soft-tissue Sarcoma
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Cone Health Cancer Center at Asheboro, Asheboro, North Carolina
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Ultrasound Simulation Case-based Workshop Implementation and Impact Assessment
NCT06960837
Recruiting
This study is a prospective cohort study implementing a point-of-care ultrasound (POCUS) simulation case-based workshop in emergency (EM) physicians at different training levels as an educational and competency-based assessment tool. The investigators incorporate elements of Miller's pyramid (second and third levels of "knows how" and "shows how") and the latter part of Kern's six step model framework for curriculum development (intervention implementation and student assessment, program evaluat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Point-of-care Ultrasound, Simulation Training, Medical Education in Emergency Ultrasound
Register for Updates
Alcohol Labeling Study
NCT06835920
Recruiting
This study aims to examine the effects of new front-of-package alcohol warnings on alcohol consumption. Participants will be randomly assigned to either new front-of-package health warnings or control labels. Participants will bring in their own alcohol to weekly study visits and take home the alcohol to consume as usual. Participants will receive study labels on their alcohol containers per their assigned trial arm.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/29/2025
Locations: UNC study office, Chapel Hill, North Carolina
Conditions: Health Behavior
Register for Updates
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
NCT06567704
Recruiting
The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Non-small Cell Lung Cancer
Register for Updates
Global Paradise System US Post Approval Study
NCT06297291
Recruiting
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina
Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Register for Updates
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
NCT05905328
Recruiting
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Cytokine Release Syndrome
Register for Updates